Cochrane · systematic review · CD009051
Hepatitis A immunisation in persons not previously exposed to hepatitis A
Irving Greg J, Holden John, Yang Rongrong, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
41
current version
GRADE rated
29
No studies
12
Included studies
NR
No studies 12 · 29.3%Ungraded 0 · 0%Very low 8 · 19.5%Low 6 · 14.6%Moderate 1 · 2.4%High 14 · 34.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Hepatitis A vaccines for preventing clinical hepatitis A in those not previously exposed
Population: patients with preventing hepatitis A.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinically apparent hepatitis A (low risk of bias trials) Dienstag 1999 | RR 0.09 [0.03, 0.3] | 3 studies · 41430 participants | High |
Clinically apparent hepatitis A (all included trials) Dienstag 1999 | RR 0.09 [0.05, 0.17] | 9 studies · 732380 participants | Very low |
Clinically apparent hepatitis A (inactivated HAV vaccines) low risk of bias trials Dienstag 1999 | RR 0.09 [0.03, 0.3] | 3 studies · 41430 participants | High |
Clinically apparent hepatitis A (inactivated HAV vaccines) all included trials Dienstag 1999 | RR 0.12 [0.05, 0.31] | 4 studies · 41690 participants | Low |
Clinically apparent hepatitis A (live attenuated HAV vaccines) low risk of bias Dienstag 1999 | no estimate extracted | NR | No studies |
Clinically apparent hepatitis A (live attenuated HAV vaccines) all included trials Dienstag 1999 | RR 0.07 [0.03, 0.17] | 5 studies · 690690 participants | Very low |
Clinically apparent hepatitis A (Dose of live attenuated HAV vaccine, titre >= TCID50 ) low risk of bias Dienstag 1999 | no estimate extracted | NR | No studies |
Clinically apparent hepatitis A (Dose of live attenuated HAV vaccine, titre >= TCID50 ) all included trials Dienstag 1999 | RR 0.03 [0.02, 0.06] | 2 studies · 62270 participants | Very low |
Clinically apparent hepatitis A (Dose of live attenuated HAV vaccine, titre < TCID50 ) low risk of bias Dienstag 1999 | no estimate extracted | NR | No studies |
Clinically apparent hepatitis A (Dose of live attenuated HAV vaccine, titre < TCID50 ) all included trials Dienstag 1999 | RR 0.11 [0.05, 0.26] | 3 studies · 628420 participants | Very low |
Clinically apparent hepatitis A (low endemicity) low risk of bias Dienstag 1999 | RR 0.19 [0.08, 0.42] | 1 study · 1037 participants | High |
Clinically apparent hepatitis A (low endemicity) all included trials Dienstag 1999 | RR 0.19 [0.08, 0.42] | 1 study · 1037 participants | High |
Clinically apparent hepatitis A (high endemicity) low risk of bias Dienstag 1999 | RR 0.05 [0.01, 0.17] | 2 studies · 40393 participants | High |
Clinically apparent hepatitis A (high endemicity) all included trials Dienstag 1999 | RR 0.08 [0.04, 0.15] | 8 studies · 731343 participants | Very low |
Clinically apparent hepatitis A (single dose regimen) low risk of bias Dienstag 1999 | RR 0.03 [0, 0.47] | 1 study · 274 participants | High |
Clinically apparent hepatitis A (single dose regimen) all included studies Dienstag 1999 | RR 0.07 [0.03, 0.15] | 6 studies · 690707 participants | Very low |
Clinically apparent hepatitis A (multiple doses) low risk of bias Dienstag 1999 | RR 0.11 [0.03, 0.4] | 2 studies · 41156 participants | High |
Clinically apparent hepatitis A (multiple doses) all included trials Dienstag 1999 | RR 0.14 [0.05, 0.37] | 3 studies · 41416 participants | Moderate |
Clinically apparent hepatitis A ( | RR 0.19 [0.08, 0.42] | 1 study · 1037 participants | High |
Clinically apparent hepatitis A ( | RR 0.2 [0.1, 0.37] | 3 studies · 2377 participants | Very low |
Clinically apparent hepatitis A ( | RR 0.05 [0.01, 0.17] | 2 studies · 40393 participants | High |
Clinicially apparent hepatitis A ( | RR 0.06 [0.02, 0.17] | 4 studies · 164776 participants | Very low |
Clinically apparent hepatitis A ( | no estimate extracted | NR | No studies |
Clinicially apparent hepatitis A ( | RR 0.05 [0.02, 0.13] | 1 study · 564642 participants | Low |
Clinically apparent hepatitis A ( | no estimate extracted | NR | No studies |
Clinically apparent hepatitis A ( | RR 0.06 [0.01, 0.41] | 1 study · 585 participants | Low |
All‐cause mortality low risk of bias Mortality | RR 1.4 [0.62, 3.16] | 1 study · 585 participants | High |
All‐cause mortality all included trials Mortality | RR 1.4 [0.62, 3.16] | 1 study · 585 participants | High |
Hepatitis A‐related mortality | no estimate extracted | NR | No studies |
Lack of sero‐protection, (anti HAV IgG < 10mIU/L) (low risk of bias) Maiwald 1997 | no estimate extracted | NR | No studies |
Lack of sero‐protection, (anti HAV IgG < 10mIU/L) (all included trials) Maiwald 1997 | no estimate extracted | NR | No studies |
Lack of sero‐protection, (anti HAV IgG < 20mIU/L) (low risk of bias ) Maiwald 1997 | RR 0.01 [0, 0.03] | 1 study · 486 participants | High |
Lack of sero‐protection, (anti HAV IgG < 20mIU/L) (all included trials) Maiwald 1997 | RR 0.01 [0, 0.03] | 2 studies · 739 participants | Low |
Non‐serious local adverse events (low risk of bias) inactivated HAV vaccine ICH‐GCP 1997 | RR 1.19 [0.67, 2.11] | 2 studies · 1299 participants | High |
Non‐serious local adverse events (all included trials) ICH‐GCP 1997 | RR 1.21 [0.86, 1.7] | 4 studies · 1559 participants | Low |
Non‐serious systemic adverse events (low risk of bias) inactivated HAV vaccine ICH‐GCP 1997 | RR 1.09 [0.67, 1.78] | 3 studies · 1299 participants | High |
Non‐serious systemic adverse events (all included studies) inactivated HAV vaccine ICH‐GCP 1997 | RR 0.98 [0.68, 1.41] | 4 studies · 1599 participants | Low |
Non‐serious local adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 | no estimate extracted | NR | No studies |
Non‐serious local adverse events (all included studies) live attenuated HAV vaccine ICH‐GCP 1997 | no estimate extracted | NR | No studies |
Non‐serious systemic adverse events (low risk of bias) live attenuated HAV vaccine ICH‐GCP 1997 | no estimate extracted | NR | No studies |
Non‐serious systemic adverse events (all included studies) live attenuated HAV vaccine ICH‐GCP 1997 | no estimate extracted | NR | No studies |